Dr. Anthony Reder is a Professor of Neurology at the University of Chicago Medical Center directing the Neurology and Inflammatory Disease Infusion Center where they treat multiple sclerosis, lupus, rheumatoid arthritis, sarcoidosis, and Crohn’s disease with leading-edge therapies.

Dr. Reder is an expert in neuroimmunology with an emphasis on multiple sclerosis (MS) and has tested most current therapies for MS, and co-developed new therapies. He has co-authored over 170 publications on multiple sclerosis.  His primary research interest is in the interaction between the central nervous system (CNS) and the cellular immune system, specifically how drugs used to treat MS modify the brain and immune system and the 9,000 genes that are abnormally activated in MS.  Professor Reder’s research laboratory focuses on the mechanism of action of interferon-beta and other MS therapies which are widely used treatments for MS and for other inflammatory diseases. His laboratory recently discovered a defect in the lymphocyte interferon signaling pathway in progressive forms of MS, possibly explaining why patients with progressive MS do not respond clinically to interferon therapy.

Dr. Reder has participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta (Betaseron), plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya) and ozanimod (Zeposia), estriol (the pregnancy hormone), natalizumab (Tysabri), and anti-CD20 therapies (Ocrevus), plus drugs for severe pain in MS such as misoprostol.  Current clinical trials include evaluating drugs that repair myelin—which insulates and enhances nerve firing and drugs that enhance neuron function.

Dr. Reder obtained his MD degree from University of Michigan, completed his residency in Neurology at University of Minnesota and a fellowship in NeuroImmunology at University of Chicago where he is now a Professor of Neurology.